131 related articles for article (PubMed ID: 16843536)
41. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate.
Blazar B; Patarroyo M; Klein E; Klein G
J Exp Med; 1980 Mar; 151(3):614-27. PubMed ID: 6244358
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of nasopharyngeal carcinoma growth by RTA-expressing baculovirus vectors containing oriP.
Wang L; Shan L; Lo KW; Yin J; Zhang Y; Sun R; Zhong J
J Gene Med; 2008 Oct; 10(10):1124-33. PubMed ID: 18642396
[TBL] [Abstract][Full Text] [Related]
43. C-1027-induced alterations in Epstein-Barr viral DNA replication in latently infected cultured human Raji cells: relationship to DNA damage.
McHugh MM; Beerman TA
Biochemistry; 1999 May; 38(21):6962-70. PubMed ID: 10346918
[TBL] [Abstract][Full Text] [Related]
44. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia.
Niller HH; Wolf H; Minarovits J
Semin Cancer Biol; 2009 Jun; 19(3):158-64. PubMed ID: 19429479
[TBL] [Abstract][Full Text] [Related]
45. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.
Kojima M; Morita Y; Nakamura N; Shimizu K; Murayama K; Nakamura S
Pathol Res Pract; 2008; 204(4):267-72. PubMed ID: 18187262
[TBL] [Abstract][Full Text] [Related]
46. Interleukin-21 regulates expression of the immediate-early lytic cycle genes and proteins in Epstein-Barr Virus infected B cells.
Konforte D; Paige CJ
Virus Res; 2009 Sep; 144(1-2):339-43. PubMed ID: 19447148
[TBL] [Abstract][Full Text] [Related]
47. Epstein-Barr virus immunossuppression of innate immunity mediated by phagocytes.
Savard M; Gosselin J
Virus Res; 2006 Aug; 119(2):134-45. PubMed ID: 16545476
[TBL] [Abstract][Full Text] [Related]
48. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.
Ressing ME; Keating SE; van Leeuwen D; Koppers-Lalic D; Pappworth IY; Wiertz EJ; Rowe M
J Immunol; 2005 Jun; 174(11):6829-38. PubMed ID: 15905524
[TBL] [Abstract][Full Text] [Related]
49. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.
Ghosh SK; Forman LW; Akinsheye I; Perrine SP; Faller DV
Blood Cells Mol Dis; 2007; 38(1):57-65. PubMed ID: 17161633
[TBL] [Abstract][Full Text] [Related]
50. Episomal replication timing of gamma-herpesviruses in latently infected cells.
Vogel B; Full F; Biesinger B; Linden C; Alberter B; Ensser A
Virology; 2010 May; 400(2):207-14. PubMed ID: 20172574
[TBL] [Abstract][Full Text] [Related]
51. Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle.
Daigle D; Gradoville L; Tuck D; Schulz V; Wang'ondu R; Ye J; Gorres K; Miller G
J Virol; 2011 Jun; 85(11):5628-43. PubMed ID: 21411522
[TBL] [Abstract][Full Text] [Related]
52. Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus.
Countryman J; Gradoville L; Bhaduri-McIntosh S; Ye J; Heston L; Himmelfarb S; Shedd D; Miller G
J Virol; 2009 Oct; 83(20):10694-709. PubMed ID: 19656890
[TBL] [Abstract][Full Text] [Related]
53. Identifying gp85-regions involved in Epstein-Barr virus binding to B-lymphocytes.
Urquiza M; Suarez J; Lopez R; Vega E; Patino H; Garcia J; Patarroyo MA; Guzman F; Patarroyo ME
Biochem Biophys Res Commun; 2004 Jun; 319(1):221-9. PubMed ID: 15158465
[TBL] [Abstract][Full Text] [Related]
54. A B-lymphocyte binding peptide from BNRF1 induced antibodies inhibiting EBV-invasion of B-lymphocytes.
López R; Urquiza M; Patino H; Suárez J; Reyes C; Patarroyo MA; Patarroyo ME
Biochimie; 2005 Nov; 87(11):985-92. PubMed ID: 15927339
[TBL] [Abstract][Full Text] [Related]
55. Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes.
Hill ER; Koganti S; Zhi J; Megyola C; Freeman AF; Palendira U; Tangye SG; Farrell PJ; Bhaduri-McIntosh S
J Virol; 2013 Nov; 87(21):11438-46. PubMed ID: 23966384
[TBL] [Abstract][Full Text] [Related]
56. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate.
Luka J; Kallin B; Klein G
Virology; 1979 Apr; 94(1):228-31. PubMed ID: 220786
[No Abstract] [Full Text] [Related]
57. Antibodies for detecting EBV latent proteins.
Rowe M; Mehl A
Methods Mol Biol; 2001; 174():219-27. PubMed ID: 11357648
[No Abstract] [Full Text] [Related]
58. The relationship between tumor promoter binding and Epstein-Barr virus induction in human lymphoblastoid cell lines.
Yamamoto N; Bauer G
J Cell Physiol; 1981 Dec; 109(3):397-402. PubMed ID: 6274878
[TBL] [Abstract][Full Text] [Related]
59. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis.
Münz C
Nat Rev Microbiol; 2019 Nov; 17(11):691-700. PubMed ID: 31477887
[TBL] [Abstract][Full Text] [Related]
60. Production of inflammatory cytokines by Epstein-Barr virus (EBV)-infected lymphoblastoid cell lines spontaneously originated from the peripheral blood of patients with human immunodeficiency virus (HIV) infection.
Roncella S; Baldi L; Cutrona G; Viale M; Rizzo F; Gasco M; Ferrarini M; Pistoia V
Clin Immunol Immunopathol; 1995 Nov; 77(2):162-71. PubMed ID: 7586723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
